Abstract
Premenstrual dysphoric disorder (PMDD) affects millions of women worldwide, and is thought to reflect suboptimal sensitivity to the GABAergic progesterone metabolite allopregnanolone (ALLO). Anxiety-potentiated startle (APS), evoked by unpredictable threat, is mediated by the ALLO-sensitive bed nucleus of the stria terminalis (BNST), and is used in this study as a marker of GABAergic sensitivity. We hypothesized that luteal (L) phase sertraline treatment will reduce premenstrual mood symptoms, and the magnitude of symptom reduction will correlate with magnitude of APS reduction. We hypothesized that fear-potentiated startle (FPS) to predictable threat, which is not mediated by BNST, will not correspond to symptom reduction.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
